Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $89
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and increased the price target from $88 to $89.
April 18, 2024 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has reaffirmed its Buy rating on CRISPR Therapeutics and raised its price target to $89, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Yigal Nochomovitz from Citigroup suggests a strong confidence in CRISPR Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100